Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.
When doctors began using the drug sotorasib in 2021 with high expectations for its innovative approach to attacking lung cancer, retired medical technician Don Crosslin was an early beneficiary. Crosslin
Active Biotech : Interview with Prof. Dr. Axel Glasmacher, Independent Board Member at Active Biotech marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Amgen plows ahead with costly, highly toxic cancer drug dosing despite FDA challenge suntimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from suntimes.com Daily Mail and Mail on Sunday newspapers.
Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge dailydemocrat.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailydemocrat.com Daily Mail and Mail on Sunday newspapers.